COVID-19 Convalescent Plasma

Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Lisa Hutchins, Pharm.D.
COVID-19 Convalescent Plasma is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • The FDA issued an updated Emergency Use Authorization (EUA, 2/4/21) permitting the use of high-titer COVID-19 convalescent plasma to treat hospitalized patients with COVID-19 early in the course of the disease and those hospitalized with impaired humoral immunity.
    • Use of convalescent plasma late in the course of illness (e.g. mechanical ventilation) has not been associated with clinical benefit.
    • The EUA encourages enrollment in available clinical trials prior to pursuing use through the EUA.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • The FDA issued an updated Emergency Use Authorization (EUA, 2/4/21) permitting the use of high-titer COVID-19 convalescent plasma to treat hospitalized patients with COVID-19 early in the course of the disease and those hospitalized with impaired humoral immunity.
    • Use of convalescent plasma late in the course of illness (e.g. mechanical ventilation) has not been associated with clinical benefit.
    • The EUA encourages enrollment in available clinical trials prior to pursuing use through the EUA.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: March 20, 2021